Skip to main content
Clinical Trials/EUCTR2015-004805-17-IT
EUCTR2015-004805-17-IT
Active, Not Recruiting
Phase 1

A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea.

Actelion Pharmaceuticals Ltd.0 sites200 target enrollmentMay 16, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Actelion Pharmaceuticals Ltd.
Enrollment
200
Status
Active, Not Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Parts A and B:
  • \- Signed informed consent by parents or legally authorized representatives (LAR) and assent by the child according to local requirements prior to initiation of any study\-mandated procedure.
  • \- Male or female from birth to \< 18 years.
  • \- Subject is diagnosed with CDAD
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 200
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Parts A and B:
  • \- Positive Rotavirus test for subjects \< 5 years.
  • \- Fulminant or life\-threatening CDAD
  • \- More than one previous episode of CDAD in the 3 month period prior to enrolment/randomization.
  • \- Antimicrobial treatment active against CDAD administered within 24 h prior to screening except for metronidazole treatment failures (MTF).
  • \- Subjects with body weight \< 3 kg.
  • \- Inflammatory bowel disease, chronic abdominal pain, or chronic diarrhea of any etiology.
  • \- Fecal microbiota transplant (FMT), immunoglobulin therapy, or any investigational drug to prevent or treat CDAD within 1 month period (or 5 half\-lives in case of investigational drug, whichever is longer) prior to enrolment/randomization.
  • \- Monoclonal antibodies against C. difficile within 6 months prior to enrolment/randomization.
  • \- Previous vaccination against C. difficile.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
A clinical study to compare the effects of cadazolid with vancomycin in children with Clostridium difficile-associated diarrhea.
EUCTR2015-004805-17-BEActelion Pharmaceuticals Ltd.200
Active, Not Recruiting
Phase 1
A clinical study to compare the effects of cadazolid with vancomycin in children with Clostridium difficile-associated diarrhea.Clostridium difficile-associated diarrhea (CDAD)MedDRA version: 20.0Level: LLTClassification code 10012734Term: Diarrhea, Clostridium difficileSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10054236Term: Clostridium difficile infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2015-004805-17-ESActelion Pharmaceuticals Ltd.1
Active, Not Recruiting
Phase 1
A clinical study to compare the effects of cadazolid with vancomycin in children with Clostridium difficile-associated diarrhea.
EUCTR2015-004805-17-HUActelion Pharmaceuticals Ltd.200
Completed
N/A
Pulmonary Hypertension in the Intensive Care Unit (ICU) - Swiss Survey 1
ISRCTN01751283Swiss Society of Pulmonary Hypertension (Switzerland)1,000
Completed
N/A
A Prospective Study, Multi-center Investigation of Impact of the Reinforced Staple Technology during Anastomosis of Laparoscopic Rectal SurgeryColon cancer
JPRN-UMIN000029543Sapporo Medical University307